Skip to main content

Advertisement

Table 3 Scenario analyses results

From: Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

Results for high risk patients (aged 65 years and requiring an ICU stay) using all available isolates Ceftolozane/tazobactam + metronidazole Piperacillin/tazobactam Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam
Total costs per patient $41,838 $42,501 -$662
Total QALYs (discounted) per patient 11.38 11.24 0.14
Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved) Dominant
Results for high risk patients (aged 65 years and requiring an ICU stay) using nosocomial isolates Ceftolozane/tazobactam + metronidazole Piperacillin/tazobactam Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam
Total costs per patient $42,979 $44,403 -$1424
Total QALYs (discounted) per patient 11.75 11.53 0.22
Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved) Dominant
Results when lifetime health care expenditure for health survivors is excluded Ceftolozane/tazobactam + metronidazole Piperacillin/tazobactam Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam
Total costs per patient $16,286 $17,265 -$978
Total QALYs (discounted) per patient 12.85 12.70 0.15
Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved)    Dominant
  1. QALY Quality Adjusted Life Year